Maribavir, brincidofovir and letermovir: Efficacy and safety of new antiviral drugs for treating cytomegalovirus infections
P Frange, M Leruez-Ville - Medecine et maladies infectieuses, 2018 - Elsevier
Cytomegalovirus (CMV) infection is a common complication in immunocompromised
patients, especially after hematopoietic stem cell or solid organ transplantation. Therapeutic
antiviral options [(val) ganciclovir, foscarnet, cidofovir] are still limited and can expose to
severe toxicities. Moreover, prolonged antiviral drug exposure and ongoing viral replication
are key factors in the development of antiviral drug resistance. After many years of few
tangible advances in terms of new antiviral drugs, we are now experiencing an exciting …
patients, especially after hematopoietic stem cell or solid organ transplantation. Therapeutic
antiviral options [(val) ganciclovir, foscarnet, cidofovir] are still limited and can expose to
severe toxicities. Moreover, prolonged antiviral drug exposure and ongoing viral replication
are key factors in the development of antiviral drug resistance. After many years of few
tangible advances in terms of new antiviral drugs, we are now experiencing an exciting …